Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio
Overview
Affiliations
To meet the anabolic demands of the proliferative potential of tumor cells, malignant cells tend to rewire their metabolic pathways. Although different types of malignant cells share this phenomenon, there is a large intracellular variability how these metabolic patterns are altered. Fortunately, differences in metabolic patterns between normal tissue and malignant cells can be exploited to increase the therapeutic ratio. Modulation of cellular metabolism to improve treatment outcome is an emerging field proposing a variety of promising strategies in primary tumor and metastatic lesion treatment. These strategies, capable of either sensitizing or protecting tissues, target either tumor or normal tissue and are often focused on modulating of tissue oxygenation, hypoxia-inducible factor (HIF) stabilization, glucose metabolism, mitochondrial function and the redox balance. Several compounds or therapies are still in under (pre-)clinical development, while others are already used in clinical practice. Here, we describe different strategies from bench to bedside to optimize the therapeutic ratio through modulation of the cellular metabolism. This review gives an overview of the current state on development and the mechanism of action of modulators affecting cellular metabolism with the aim to improve the radiotherapy response on tumors or to protect the normal tissue and therefore contribute to an improved therapeutic ratio.
Exploring the Metabolic Impact of FLASH Radiotherapy.
Geirnaert F, Kerkhove L, Montay-Gruel P, Gevaert T, Dufait I, De Ridder M Cancers (Basel). 2025; 17(1.
PMID: 39796760 PMC: 11720285. DOI: 10.3390/cancers17010133.
Novel radiation and targeted therapy combinations for improving rectal cancer outcomes.
Pennel K, Dutton L, Melissourgou-Syka L, Roxburgh C, Birch J, Edwards J Expert Rev Mol Med. 2024; 26:e14.
PMID: 38623751 PMC: 11140547. DOI: 10.1017/erm.2024.15.
The Role of Regulatory T Cells in Cancer Treatment Resistance.
Dabrowska A, Grubba M, Balihodzic A, Szot O, Sobocki B, Perdyan A Int J Mol Sci. 2023; 24(18).
PMID: 37762416 PMC: 10531820. DOI: 10.3390/ijms241814114.
Immunometabolic reprogramming, another cancer hallmark.
Kumar V, Stewart 4th J Front Immunol. 2023; 14:1125874.
PMID: 37275901 PMC: 10235624. DOI: 10.3389/fimmu.2023.1125874.
Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance.
Bailleul J, Vlashi E Antioxid Redox Signal. 2023; 39(13-15):957-979.
PMID: 37022791 PMC: 10655009. DOI: 10.1089/ars.2022.0088.